Annals of Oncology最新文献

筛选
英文 中文
A randomized phase I study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine-tipiracil with bevacizumab in patients with metastatic colorectal cancer. 一项针对转移性结直肠癌患者的telisotuzumab adizutecan (ABBV-400, Temab-A)联合贝伐单抗与trifluriddine -tipiracil联合贝伐单抗的随机一期研究。
IF 80.4 1区 医学
Annals of Oncology Pub Date : 2026-10-24 DOI: 10.1016/j.annonc.2026.10.105
M Cecchini, M Cruz-Correa, S-W Han, K Raghav, A Landa-Magdalena, J H Strickler, A Calvo, A Hollebecque, T E Nakajima, G Perl, V Jain, Z Hunter, E M Chan, M Blaney, R Li, A Vasilopoulos, A Parikh, M R Sharma
{"title":"A randomized phase I study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine-tipiracil with bevacizumab in patients with metastatic colorectal cancer.","authors":"M Cecchini, M Cruz-Correa, S-W Han, K Raghav, A Landa-Magdalena, J H Strickler, A Calvo, A Hollebecque, T E Nakajima, G Perl, V Jain, Z Hunter, E M Chan, M Blaney, R Li, A Vasilopoulos, A Parikh, M R Sharma","doi":"10.1016/j.annonc.2026.10.105","DOIUrl":"10.1016/j.annonc.2026.10.105","url":null,"abstract":"<p><strong>Background: </strong>Telisotuzumab adizutecan (ABBV-400, Temab-A) is an antibody-drug conjugate targeting c-Met (MET) protein with adizutecan, a novel topoisomerase 1 inhibitor payload. In monotherapy dose escalation, Temab-A demonstrated a manageable safety profile and promising antitumor activity in advanced colorectal cancer (CRC; NCT05029882). Based on these results, a randomized cohort of Temab-A + bevacizumab (Bev) versus trifluridine-tipiracil (FTD-TPI) + Bev (standard of care) was added with the hypothesis that addition of Bev would enhance efficacy.</p><p><strong>Patients and methods: </strong>Patients unselected for c-Met protein expression with advanced CRC were enrolled in two parts. In dose escalation, patients received Temab-A 1.6, 2.0, or 2.4 mg/kg + Bev 7.5 mg/kg every 3 weeks. In dose optimization, patients were randomly assigned to receive 1 : 1 : 1 Temab-A 2.0 or 2.4 mg/kg + Bev 7.5 mg/kg every 3 weeks, or FTD-TPI 35 mg/m<sup>2</sup> days 1-5 and 8-12 every 4 weeks + Bev 5.0 mg/kg every 2 weeks. Primary objectives were safety, pharmacokinetics, and efficacy of Temab-A + Bev.</p><p><strong>Results: </strong>Overall, 83 patients received treatment with Temab-A + Bev (n = 63) or FTD-TPI + Bev (n = 20) with median 3 (range, 1-8) prior lines of treatment and median follow-up of 18.2 months. Treatment-related adverse events were primarily gastrointestinal and hematological with low discontinuation rates [Temab-A 2.0: 3/26 (12%); Temab-A 2.4: 1/30 (3%)]. Objective response rate was 19% and 30% with Temab-A 2.0 and 2.4 + Bev, respectively, and 0% with FTD-TPI + Bev. For Temab-A 2.0 and 2.4 + Bev versus FTD-TPI + Bev, median progression-free survival was 5.6 and 6.8 versus 4.2 months; median overall survival was 11.2 (HR 0.75) and 14.7 (HR 0.62) versus 10.2 months, respectively.</p><p><strong>Conclusions: </strong>Temab-A 2.4 mg/kg + Bev demonstrated the most favorable risk-benefit profile, was tolerable, and had clinically meaningful improvements in efficacy versus FTD-TPI + Bev for advanced CRC. The regimen is being evaluated in the global randomized phase III trial AndroMETa-CRC-560 (NCT07525206).</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":80.4,"publicationDate":"2026-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149261092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR-positive, HER2-negative advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy. abemaciclib加氟维司汀vs安慰剂加氟维司汀治疗先前CDK4/6抑制剂加内分泌治疗进展后的HR+、HER2晚期乳腺癌的III期后期君主试验的总生存率。
IF 80.4 1区 医学
Annals of Oncology Pub Date : 2026-10-24 DOI: 10.1016/j.annonc.2026.10.1283
K Kalinsky, S A Wander, E Hamilton, S L Graff, R Jeselsohn, K H Park, U Demirci, M Martin, R M Layman, S A Hurvitz, S Sammons, P A Kaufman, E Ravenberg, S Amdur, L M Litchfield, G Bianchini
{"title":"Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR-positive, HER2-negative advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy.","authors":"K Kalinsky, S A Wander, E Hamilton, S L Graff, R Jeselsohn, K H Park, U Demirci, M Martin, R M Layman, S A Hurvitz, S Sammons, P A Kaufman, E Ravenberg, S Amdur, L M Litchfield, G Bianchini","doi":"10.1016/j.annonc.2026.10.1283","DOIUrl":"10.1016/j.annonc.2026.10.1283","url":null,"abstract":"<p><strong>Background: </strong>The phase III postMONARCH trial demonstrated a statistically significant improvement in progression-free survival (PFS) with abemaciclib plus fulvestrant versus placebo plus fulvestrant in participants with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) after disease progression on prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET). Here, we report the prespecified final overall survival (OS) analysis.</p><p><strong>Participants and methods: </strong>Eligible patients had disease progression on a CDK4/6i plus aromatase inhibitor as initial therapy for ABC or recurrence on or after adjuvant CDK4/6i plus ET. Participants were randomly assigned 1 : 1 to receive abemaciclib plus fulvestrant or placebo plus fulvestrant. The final OS analysis was prespecified at 200 OS events (HR boundary 0.753). Time-to-event analyses used the Kaplan-Meier method, and stratified Cox models were used to estimate the HR and 95% confidence intervals (CIs).</p><p><strong>Results: </strong>A total of 368 participants were randomly assigned 1 : 1 to abemaciclib plus fulvestrant (n = 182) or placebo plus fulvestrant (n = 186). At data cut-off, the median follow-up was ∼37 months; 200 OS events were observed [90 (50%) versus 110 (59%)]. Median OS was 32.1 months with abemaciclib plus fulvestrant versus 24.6 months with placebo plus fulvestrant (HR 0.80, 95% CI 0.60-1.06, P = 0.11, boundary for significance not reached). OS differences were consistent across subgroups. Updated PFS was consistent with the primary analysis (HR 0.78, 95% CI 0.62-0.99, nominal P = 0.039). Time to secondly progression and chemotherapy-free survival also favored abemaciclib plus fulvestrant. Safety was consistent with the established abemaciclib profile with no new signals identified.</p><p><strong>Conclusion: </strong>Abemaciclib plus fulvestrant resulted in a numerically longer median OS versus placebo plus fulvestrant, although statistical significance was not reached. The totality of evidence supports the consideration of abemaciclib-based treatment of patients with hormone receptor-positive, HER2-negative ABC after disease progression on prior CDK4/6i plus ET.</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":80.4,"publicationDate":"2026-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149261164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adjuvant chemotherapy with cisplatin and gemcitabine compared with standard of care after curative intent resection of cholangiocarcinoma and muscle-invasive gallbladder carcinoma (ACTICCA-1/AIO-HEP-0112 trial). 顺铂和吉西他滨辅助化疗与胆管癌和肌肉浸润性胆囊癌术后标准治疗的比较(actica -1/AIO-HEP-0112试验)。
IF 80.4 1区 医学
Annals of Oncology Pub Date : 2026-10-24 DOI: 10.1016/j.annonc.2026.10.1278
A Stein, J Bridgewater, H-J Klümpen, T Gruenberger, J Shannon, L Fornaro, L H Jensen, D Arnold, J Primrose, D Goldstein, A W Lohse, J Wilmink, U Pession, D P Modest, S Kasper, H S Wasan, D Palmer, J de Vos-Geelen, G Folprecht, A Möhl, A Pepić, E Vettorazzi, H Wege
{"title":"Adjuvant chemotherapy with cisplatin and gemcitabine compared with standard of care after curative intent resection of cholangiocarcinoma and muscle-invasive gallbladder carcinoma (ACTICCA-1/AIO-HEP-0112 trial).","authors":"A Stein, J Bridgewater, H-J Klümpen, T Gruenberger, J Shannon, L Fornaro, L H Jensen, D Arnold, J Primrose, D Goldstein, A W Lohse, J Wilmink, U Pession, D P Modest, S Kasper, H S Wasan, D Palmer, J de Vos-Geelen, G Folprecht, A Möhl, A Pepić, E Vettorazzi, H Wege","doi":"10.1016/j.annonc.2026.10.1278","DOIUrl":"10.1016/j.annonc.2026.10.1278","url":null,"abstract":"<p><strong>Background: </strong>Despite curative resection and adjuvant capecitabine, ∼50% of patients with biliary tract cancer (BTC) have tumour recurrence or die within 2 years. This study evaluated the established palliative chemotherapy regimen with cisplatin and gemcitabine (CisGem) in the adjuvant setting.</p><p><strong>Patients and methods: </strong>ACTICCA-1 is a randomised, phase III investigator-initiated trial. Patients were enrolled at 67 sites across 8 countries between September 2017 and January 2023 and randomised to CisGem or capecitabine as adjuvant treatment regimen, each for a planned duration of 24 weeks. The primary endpoint is disease-free survival (DFS). Secondary endpoints include overall survival (OS), safety, and tolerability.</p><p><strong>Results: </strong>In total, 591 patients have been randomly assigned. Median follow-up was 4.8 years. Median age was 63 years, 46.9% were women, and median interval between surgery and enrolment was 67 days. Primary tumour location was intrahepatic in 28.3%, perihilar in 19%, distal in 36.5%, and gallbladder in 16.2%; 47.9% of patients had lymph node-positive disease. CisGem showed a median DFS of 25.7 compared with 17.9 months for capecitabine (log rank P = 0.097). As predefined in the statistical analysis plan, due to violation of proportional hazard assumption, a Cox model was not feasible, and restricted mean survival time (RMST) was analysed. Patients receiving CisGem experienced on average 2.6 additional DFS months (95% confidence interval 0.6-4.68) compared with capecitabine (RMST in the first 3 years, P = 0.011), but no significant improvement in OS was observed (RMST P = 0.076; median 58.1 versus 48.2 months). Toxicity showed a higher number of severe adverse events (AEs; 130 versus 113 with 51 versus 47 assessed as treatment related) and a higher AE rate with CisGem (74.7%) compared with capecitabine (69.5%).</p><p><strong>Conclusion: </strong>CisGem did not statistically improve DFS compared with capecitabine and should thus not be applied as standard of care in the adjuvant setting.</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":80.4,"publicationDate":"2026-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149261153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Capivasertib plus abiraterone in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer: updated survival analysis from CAPItello-281. Capivasertib联合阿比特龙治疗pten缺陷新发转移性激素敏感前列腺癌:来自CAPItello-281的最新生存分析
IF 80.4 1区 医学
Annals of Oncology Pub Date : 2026-10-23 DOI: 10.1016/j.annonc.2026.10.097
K Fizazi, N W Clarke, M De Santis, H Uemura, A P Fay, N Karadurmus, C Alvarez-Fernandez, S Jiang, D Parslow, M Sotelo, Y Ürün, N Oliveira, T Gyun Kwon, M Özgüroğlu, G Roubaud, D Castellano, J K Logan, T Morris, C Gresty, D J George
{"title":"Capivasertib plus abiraterone in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer: updated survival analysis from CAPItello-281.","authors":"K Fizazi, N W Clarke, M De Santis, H Uemura, A P Fay, N Karadurmus, C Alvarez-Fernandez, S Jiang, D Parslow, M Sotelo, Y Ürün, N Oliveira, T Gyun Kwon, M Özgüroğlu, G Roubaud, D Castellano, J K Logan, T Morris, C Gresty, D J George","doi":"10.1016/j.annonc.2026.10.097","DOIUrl":"10.1016/j.annonc.2026.10.097","url":null,"abstract":"<p><strong>Background: </strong>Patients with phosphatase and tensin homolog (PTEN)-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC) have poor prognosis and reduced benefit from current standard of care. The phase III CAPItello-281 study (NCT04493853) showed a statistically significant benefit in radiographic progression-free survival (rPFS) with capivasertib plus abiraterone versus placebo plus abiraterone (combined with prednisone/prednisolone and androgen deprivation therapy): hazard ratio (HR) 0.81, 95% confidence interval (CI) 0.66-0.98; P = 0.034. The HR for interim overall survival (OS; 26% maturity) was 0.90, 95% CI 0.71-1.15. Here, we report ad hoc, descriptive analyses at 42% OS data maturity.</p><p><strong>Patients and methods: </strong>Patients with de novo mHSPC and PTEN-deficient tumors (defined as ≥90% of viable malignant cells with no specific cytoplasmic staining by immunohistochemistry) received capivasertib plus abiraterone or matched placebo (randomly assigned 1 : 1) plus abiraterone. Analyses carried out at this ad hoc data cut-off, including the alpha-controlled key secondary endpoint of OS as well as the primary endpoint of investigator-assessed rPFS, were descriptive and not prespecified in the protocol.</p><p><strong>Results: </strong>A total of 1012 patients received capivasertib plus abiraterone (n = 507) or placebo plus abiraterone (n = 505). At this ad hoc analysis at 42% OS maturity (data cut-off: 9 March 2026), with 17 months' additional follow-up (median follow-up 39 months in both arms), HR for OS favored capivasertib plus abiraterone versus placebo plus abiraterone (HR 0.82, 95% CI 0.68-0.99, P = 0.044) and OS medians were reached: 57.4 versus 46.5 months. Updated rPFS (HR 0.83, 95% CI 0.70-0.99, nominal P = 0.033; median 35.5 versus 26.0 months) was consistent with the primary analysis. The safety profile remained consistent with the primary findings.</p><p><strong>Conclusions: </strong>With longer follow-up, findings from this updated descriptive analysis support the clinically meaningful OS benefit of adding capivasertib to abiraterone in the treatment of patients with PTEN-deficient mHSPC. Capivasertib plus abiraterone represents a first-in-class targeted treatment approach for this poor prognosis population with high unmet need.</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":80.4,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149242783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nivolumab plus relatlimab with platinum-doublet chemotherapy versus nivolumab with platinum-doublet chemotherapy in stage IV or recurrent non-small cell lung cancer: clinical, translational, and patient-reported outcomes results from the phase II RELATIVITY-104 study. 在IV期或复发性非小细胞肺癌中,Nivolumab + relatlimumab +铂双药化疗vs . Nivolumab +铂双药化疗:来自II期RELATIVITY-104研究的临床、转化和患者报告结果
IF 80.4 1区 医学
Annals of Oncology Pub Date : 2026-10-23 DOI: 10.1016/j.annonc.2026.10.103
N Girard, M Burotto, L G Paz-Ares, M Schenker, A Lingua, F Orlandi, J Naidoo, E K Beardsley, V Velcheti, G L Martinengo, E Felip, M Reck, A Qureshi, P Kasbekar, S Samanta, J Neely, Charlie Garnett-Benson, L McDonald, J X Yu, M Cobo-Dols
{"title":"Nivolumab plus relatlimab with platinum-doublet chemotherapy versus nivolumab with platinum-doublet chemotherapy in stage IV or recurrent non-small cell lung cancer: clinical, translational, and patient-reported outcomes results from the phase II RELATIVITY-104 study.","authors":"N Girard, M Burotto, L G Paz-Ares, M Schenker, A Lingua, F Orlandi, J Naidoo, E K Beardsley, V Velcheti, G L Martinengo, E Felip, M Reck, A Qureshi, P Kasbekar, S Samanta, J Neely, Charlie Garnett-Benson, L McDonald, J X Yu, M Cobo-Dols","doi":"10.1016/j.annonc.2026.10.103","DOIUrl":"https://doi.org/10.1016/j.annonc.2026.10.103","url":null,"abstract":"<p><strong>Background: </strong>Programmed death 1-blocking antibody, nivolumab, plus lymphocyte-activation gene 3-blocking antibody, relatlimab, is approved for advanced melanoma. We report results from Part 2 of RELATIVITY-104, the first phase II, proof-of-concept, head-to-head study to evaluate first-line nivolumab plus relatlimab plus platinum doublet chemotherapy (PDCT) versus nivolumab plus PDCT in patients with stage IV/recurrent non-small cell lung cancer (NSCLC).</p><p><strong>Patients and methods: </strong>In Part 2, patients were randomized 1:1 to nivolumab plus relatlimab plus PDCT or nivolumab plus PDCT. The primary endpoint was objective response rate (ORR) per blinded independent central review (BICR). Secondary endpoints included progression-free survival (PFS) and duration of response (DOR) per BICR, ORR and PFS by subgroups, and safety. Exploratory analyses included overall survival (OS), biomarker, translational, and patient-reported outcomes.</p><p><strong>Results: </strong>In part 2, the primary endpoint was not met (ORR, 51.3% for nivolumab plus relatlimab plus PDCT versus 45.0% for nivolumab plus PDCT); PFS hazard ratio (HR; 90% confidence interval [CI]) was 0.89 (0.72 to 1.09). A trend towards improved clinical benefit was seen with nivolumab plus relatlimab plus PDCT in a subgroup of patients with programmed death ligand 1 (PD-L1) ≥1% and nonsquamous histology (ORR: 58.0% versus 39.6%; PFS: HR, 0.68; 90% CI 0.46 to 1.01). A potential improvement in OS was observed with nivolumab plus relatlimab plus PDCT in the PD-L1 ≥1% nonsquamous subgroup (HR, 0.60; 90% CI 0.38 to 0.94). The safety profile of nivolumab plus relatlimab plus PDCT was manageable and consistent with previous reports.</p><p><strong>Conclusion: </strong>In RELATIVITY-104, the addition of relatlimab to standard-of-care did not improve outcomes in the unselected all-randomized population. However, positive trends observed in the subgroup of patients with tumor PD-L1 ≥1% and nonsquamous NSCLC supports further investigation in these patients in the phase III RELATIVITY-1093 study.</p><p><strong>Clinicaltrials: </strong>gov identifier: NCT04623775.</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":80.4,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149242807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neoadjuvant nivolumab plus gemcitabine-cisplatin followed by postsurgical adjuvant nivolumab versus neoadjuvant gemcitabine-cisplatin in patients with muscle-invasive bladder cancer: final results from the phase III CA017-078 trial. 新辅助纳武单抗联合吉西他滨-顺铂治疗肌肉浸润性膀胱癌患者,术后辅助纳武单抗联合新辅助吉西他滨-顺铂治疗:来自CA017-078 III期试验的最终结果
IF 80.4 1区 医学
Annals of Oncology Pub Date : 2026-10-23 DOI: 10.1016/j.annonc.2026.10.096
G Sonpavde, M S van der Heijden, S Gupta, M D Galsky, G Steinberg, J E Gschwend, J P Sade, D Bimbatti, U De Giorgi, G Schepisi, S Vázquez Estévez, S Panay, G Schinzari, A Kotsakis, H Miyake, J J Oh, J Zhang, C Jeyamohan, J Neely, M Jacques, Q Duong, S Sarkar, A Necchi
{"title":"Neoadjuvant nivolumab plus gemcitabine-cisplatin followed by postsurgical adjuvant nivolumab versus neoadjuvant gemcitabine-cisplatin in patients with muscle-invasive bladder cancer: final results from the phase III CA017-078 trial.","authors":"G Sonpavde, M S van der Heijden, S Gupta, M D Galsky, G Steinberg, J E Gschwend, J P Sade, D Bimbatti, U De Giorgi, G Schepisi, S Vázquez Estévez, S Panay, G Schinzari, A Kotsakis, H Miyake, J J Oh, J Zhang, C Jeyamohan, J Neely, M Jacques, Q Duong, S Sarkar, A Necchi","doi":"10.1016/j.annonc.2026.10.096","DOIUrl":"10.1016/j.annonc.2026.10.096","url":null,"abstract":"<p><strong>Background: </strong>Perioperative immune checkpoint inhibition improves outcomes in muscle-invasive bladder cancer (MIBC). The phase III, randomized CA017-078 (ENERGIZE; NCT03661320) trial evaluated perioperative nivolumab plus neoadjuvant gemcitabine-cisplatin (GC) versus neoadjuvant GC alone for previously untreated, resectable MIBC.</p><p><strong>Patients and methods: </strong>Adults with previously untreated cT2-T4aN0M0 MIBC eligible for radical cystectomy (RC) and cisplatin were randomized to neoadjuvant nivolumab plus GC followed by RC and adjuvant nivolumab (nivolumab plus GC arm), or neoadjuvant GC followed by RC alone (GC arm). Coprimary endpoints were pathologic documented complete response (pCR; defined as ypT0N0) and event-free survival (EFS). Overall survival (OS) was a secondary endpoint within the prespecified hierarchical testing strategy, and formal testing was contingent on a statistically significant EFS result.</p><p><strong>Results: </strong>At this final analysis with 54.5 months of median follow-up, 325 patients were randomized to the nivolumab plus GC arm, 328 to the GC arm. pCR rates were 39.1% and 29.6%, respectively [adjusted difference 9.5%, 99.91% confidence interval (CI) -2.6 to 21.6]. EFS was not improved in the nivolumab plus GC versus GC arm [104 events in each arm; hazard ratio (HR) 0.94, 95.74% CI 0.71-1.25; P = 0.6697]. OS was summarized descriptively because EFS did not meet the testing criterion (HR 0.88, 95% CI 0.64-1.21). Grade 3-4 treatment-related adverse events occurred in 50.0% compared with 49.5%; one treatment-related death occurred with nivolumab plus GC. Pretreatment circulating tumor DNA (ctDNA) was positive in 229 of 416 tested patients (55%) overall, 108 of 211 (51%) in the GC arm, and 121 of 205 (59%) in the nivolumab plus GC arm. Clearance by cycle 4 day 1 (C4D1) occurred in 153 of 199 patients (76.9%) overall, 87 of 107 (81.3%) with nivolumab plus GC, and 66 of 92 (71.7%) with GC. ctDNA detection at baseline and at C4D1 was associated with shorter EFS and OS.</p><p><strong>Conclusions: </strong>The addition of perioperative nivolumab to neoadjuvant GC did not improve outcomes and was associated with predictable toxicity. Exploratory analysis showed ctDNA was strongly prognostic.</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":80.4,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149242826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+/HER2- early breast cancer: Six-year follow-up of the NATALEE trial. 高危HR+/HER2-早期乳腺癌患者使用辅助核糖环尼加非甾体芳香化酶抑制剂的总生存率:NATALEE试验的6年随访
IF 80.4 1区 医学
Annals of Oncology Pub Date : 2026-10-23 DOI: 10.1016/j.annonc.2026.10.1288
D J Slamon, G N Hortobagyi, D Stroyakovskiy, D A Yardley, C-S Huang, J Crown, A Bardia, S Chia, S-A Im, M Martin, S Loi, B Xu, S A Hurvitz, C H Barrios, A Cuesta Fernández, M Untch, F Visco, A L Perez, M Miller, S Majumdar, S Peyrard, T Taran, P A Fasching
{"title":"Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+/HER2- early breast cancer: Six-year follow-up of the NATALEE trial.","authors":"D J Slamon, G N Hortobagyi, D Stroyakovskiy, D A Yardley, C-S Huang, J Crown, A Bardia, S Chia, S-A Im, M Martin, S Loi, B Xu, S A Hurvitz, C H Barrios, A Cuesta Fernández, M Untch, F Visco, A L Perez, M Miller, S Majumdar, S Peyrard, T Taran, P A Fasching","doi":"10.1016/j.annonc.2026.10.1288","DOIUrl":"https://doi.org/10.1016/j.annonc.2026.10.1288","url":null,"abstract":"<p><strong>Background: </strong>Ribociclib plus nonsteroidal aromatase inhibitor (NSAI) demonstrated a statistically significant invasive disease-free survival (iDFS) benefit over NSAI alone in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC) at the primary efficacy analysis of the phase 3 NATALEE trial. This prespecified 6-year analysis assessed overall survival (OS) and other efficacy outcomes as well as safety.</p><p><strong>Patients and methods: </strong>Eligible patients were adults with HR+/HER2- EBC and anatomic stage IIA (N1 or N0 with high-risk factors), IIB, or III disease. Enrolled patients were randomized 1:1 to ribociclib 400 mg/day (3 weeks on/1 week off for 3 years) plus NSAI (letrozole 2.5 mg/day or anastrozole 1 mg/day for 5 years) or NSAI alone. Premenopausal women and men also received goserelin. The primary endpoint was iDFS, and secondary/exploratory endpoints included OS, distant disease-free survival (DDFS), and distant recurrence-free survival (DRFS).</p><p><strong>Results: </strong>With a median OS follow-up of 66.5 months, ribociclib plus NSAI demonstrated an OS benefit over NSAI alone (6-year ΔOS, 2.1%; HR, 0.809 [95% CI: 0.661-0.989]; nominal 1-sided P = .019), which was generally consistent across key subgroups. An increasing iDFS benefit with ribociclib plus NSAI was also observed (6-year ΔiDFS, 5.3%; HR, 0.741 [95% CI: 0.646-0.849]; nominal 1-sided P < .0001), which was also generally consistent across key subgroups. DDFS (HR, 0.744 [95% CI: 0.646-0.858]) and DRFS (HR, 0.738 [95% CI: 0.634-0.858]) results supported these findings. No new safety signals were observed.</p><p><strong>Conclusions: </strong>This prespecified descriptive 6-year OS analysis demonstrated positive OS results with a clinically relevant benefit of ribociclib plus NSAI, consistent with the increasing reduction in recurrence risk. These results reinforce the benefit of ribociclib plus NSAI in the adjuvant setting across the broad NATALEE-eligible population.</p><p><strong>Clinical trial registration: </strong>NCT03701334 (ClinicalTrials.gov).</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":80.4,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149242758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perioperative pembrolizumab or placebo plus neoadjuvant cisplatin and gemcitabine in participants with muscle-invasive bladder cancer who are eligible for cisplatin: the double-blind, phase III KEYNOTE-866 study. 适合顺铂治疗的肌肉浸润性膀胱癌患者围手术期使用派姆单抗或安慰剂加新辅助顺铂和吉西他滨:双盲III期KEYNOTE-866研究
IF 80.4 1区 医学
Annals of Oncology Pub Date : 2026-10-23 DOI: 10.1016/j.annonc.2026.10.106
J Bedke, P Arkosy, H Nishiyama, H Mahammedi, C Vulsteke, M J Juan-Fita, I Antonyan, O Didas, E Verzoni, V Atduev, A Rodriguez-Vida, J J Oh, S-H Kang, A Peer, R Zukov, B Zurawksi, M Gümüş, G D Steinberg, J Olah, S Abadie-Lacourtoisie, N Jain, S Franco, B Homet Moreno, C J Hoimes, A Siefker-Radtke
{"title":"Perioperative pembrolizumab or placebo plus neoadjuvant cisplatin and gemcitabine in participants with muscle-invasive bladder cancer who are eligible for cisplatin: the double-blind, phase III KEYNOTE-866 study.","authors":"J Bedke, P Arkosy, H Nishiyama, H Mahammedi, C Vulsteke, M J Juan-Fita, I Antonyan, O Didas, E Verzoni, V Atduev, A Rodriguez-Vida, J J Oh, S-H Kang, A Peer, R Zukov, B Zurawksi, M Gümüş, G D Steinberg, J Olah, S Abadie-Lacourtoisie, N Jain, S Franco, B Homet Moreno, C J Hoimes, A Siefker-Radtke","doi":"10.1016/j.annonc.2026.10.106","DOIUrl":"https://doi.org/10.1016/j.annonc.2026.10.106","url":null,"abstract":"<p><strong>Background: </strong>Perioperative PD-(L)1 inhibitors, either combined with cisplatin-based chemotherapy or enfortumab vedotin, have improved outcomes in patients with muscle-invasive bladder cancer (MIBC) who are cisplatin eligible. The double-blind, phase III KEYNOTE-866 study evaluated perioperative (neoadjuvant and adjuvant) pembrolizumab versus placebo added to neoadjuvant cisplatin plus gemcitabine (chemotherapy) and radical cystectomy with pelvic lymph node dissection (cystectomy) in MIBC.</p><p><strong>Patients and methods: </strong>Eligible participants were aged ≥18 years, had centrally assessed clinical stage T2-T4aN0M0 or T1-T4aN1M0 MIBC with ≥50% urothelial histology, and were eligible for cisplatin-based chemotherapy and cystectomy. Participants were randomly assigned (1:1) to neoadjuvant pembrolizumab or placebo plus chemotherapy every 3 weeks for 4 cycles, followed by cystectomy, and adjuvant pembrolizumab or placebo every 3 weeks for 13 cycles (pembrolizumab or placebo group, respectively). Primary end point was event-free survival (EFS) by investigator assessment. Pathological complete response (pCR) rate by blinded independent central pathological review and overall survival (OS) were key secondary end points. Safety was a secondary end point.</p><p><strong>Results: </strong>Overall, 907 participants were randomly assigned (pembrolizumab, n = 453; placebo, n = 454). Median follow-up was 60.9 months (range, 40.7-78.7). At 60 months, the estimated EFS rate was 63.5% with pembrolizumab versus 61.9% with placebo (hazard ratio 0.88; 95% CI 0.71-1.10; one-sided P = 0.1366). The pCR rate was 44.4% versus 35.8% (estimated difference 8.9%; 95% CI 2.5-15.1); median OS was not reached in both groups (hazard ratio 1.00; 95% CI 0.79-1.27). Treatment-emergent adverse events occurred in 99.8% of participants in the pembrolizumab group (grade ≥3 in 80.2%) and 98.7% in the placebo group (grade ≥3 in 75.1%).</p><p><strong>Conclusions: </strong>The addition of perioperative pembrolizumab to neoadjuvant chemotherapy and cystectomy did not confer a statistically significant EFS benefit in participants with MIBC who are cisplatin eligible. The safety profile of pembrolizumab was manageable and consistent with prior reports.</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":80.4,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149242789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Active surveillance versus standard surgery after neoadjuvant chemoradiotherapy for oesophageal cancer: long-term results of a cluster-randomised controlled trial (SANO). 食管癌新辅助放化疗后主动监测与标准手术:一项聚类随机对照试验(SANO)的长期结果
IF 80.4 1区 医学
Annals of Oncology Pub Date : 2026-10-23 DOI: 10.1016/j.annonc.2026.10.1290
S S G Gangaram Panday, B J van der Wilk, S M Lagarde, B M Eyck, C Rosman, B J Noordman, M J Valkema, T M Bisseling, P P L O Coene, M J van Det, J W T Dekker, J M van Dieren, M Doukas, S van Esser, W E Fiets, H H Hartgrink, J Heisterkamp, I L Holster, B Klarenbeek, E Kouw, E A Kouwenhoven, M D Luyer, B Mostert, G A P Nieuwenhuijzen, L E Oostenbrug, J P Pierie, J W van Sandick, M N Sosef, M C W Spaander, R Valkema, E S van der Zaag, E W Steyerberg, D van Klaveren, B P L Wijnhoven, J J B van Lanschot
{"title":"Active surveillance versus standard surgery after neoadjuvant chemoradiotherapy for oesophageal cancer: long-term results of a cluster-randomised controlled trial (SANO).","authors":"S S G Gangaram Panday, B J van der Wilk, S M Lagarde, B M Eyck, C Rosman, B J Noordman, M J Valkema, T M Bisseling, P P L O Coene, M J van Det, J W T Dekker, J M van Dieren, M Doukas, S van Esser, W E Fiets, H H Hartgrink, J Heisterkamp, I L Holster, B Klarenbeek, E Kouw, E A Kouwenhoven, M D Luyer, B Mostert, G A P Nieuwenhuijzen, L E Oostenbrug, J P Pierie, J W van Sandick, M N Sosef, M C W Spaander, R Valkema, E S van der Zaag, E W Steyerberg, D van Klaveren, B P L Wijnhoven, J J B van Lanschot","doi":"10.1016/j.annonc.2026.10.1290","DOIUrl":"https://doi.org/10.1016/j.annonc.2026.10.1290","url":null,"abstract":"<p><strong>Background: </strong>The Surgery As Needed for Oesophageal cancer (SANO)-trial demonstrated that active surveillance is non-inferior to standard surgery in terms of two-year overall survival in patients with a complete clinical response after neoadjuvant chemoradiotherapy (nCRT). Active surveillance resulted in improved quality of life. Here, we report five-year outcomes.</p><p><strong>Methods: </strong>From 2017 to 2021, a multicentre stepped-wedge cluster-randomised non-inferiority trial was conducted. Patients with locally advanced oesophageal cancer who achieved complete clinical response (defined as no tumour detected on endoscopic biopsies, -ultrasound, or PET-CT) underwent active surveillance or standard surgery. Cox regression was used to compare five-year overall and disease-free survival, and the cumulative incidence of distant metastases was estimated using competing risk analysis.</p><p><strong>Results: </strong>A total of 309 patients were included, 198 underwent active surveillance and 111 underwent standard surgery. Median follow-up was 76 months (IQR 67-86). Five-year overall survival was not statistically significantly different between active surveillance and standard surgery (50%, 95%CI 43-57 vs. 54%, 95%CI 46-64; HR 1.17, 95%CI 0.77-1.77) with similar results across histologic subtypes. Disease-free survival was not statistically significantly different (HR 1.39, 95% CI 0.94-2.06). The cumulative incidence of distant metastases at five years was significantly higher in the active surveillance group compared to the standard surgery group (46%, 95%CI 39-53 vs. 29%, 95%CI 21-37; P<.01). Overall, 85 of 198 patients (43%) avoided oesophagectomy, including those with sustained complete clinical response at last follow-up or distant metastases detected within six months after nCRT.</p><p><strong>Conclusions: </strong>Overall survival at five years is not statistically significantly different between active surveillance and standard surgery in patients with oesophageal cancer and a complete clinical response after nCRT, despite a higher incidence of distant metastases in the active surveillance group. These findings support active surveillance as a feasible treatment strategy in selected patients.</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":80.4,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149242840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The ESMO Scale for Clinical Actionability of Molecular Targets, version 2 (ESCAT v2): an evidence-based framework for ranking alterations as actionability and resistance biomarkers in precision oncology. ESMO分子靶点临床可操作性量表,第2版(ESCAT v2):一个基于证据的框架,用于将变化作为精确肿瘤学的可操作性和耐药生物标志物进行排名。
IF 80.4 1区 医学
Annals of Oncology Pub Date : 2026-10-21 DOI: 10.1016/j.annonc.2026.09.008
Aya El Helali, Claudia Cardone, Niamh Coleman, Juliana R Beal, Mel Valerie Cruz-Ordinario, Emre Kocakavuk, Matthew Kin-Liang Chiu, David Thomas, Clare Turnbull, Funda Meric-Bernstam, Maria Fernanda Mosele, Debyani Chakravarty, Rodrigo Dienstmann, David Tamborero, Hege E G Russnes, Maximilian Kordes, Herbert Ho Fung Loong, Albrecht Stenzinger, Jens Rueter, Diogo Martins-Branco, George Pentheroudakis, Joaquin Mateo, Christoph Benedikt Westphalen
{"title":"The ESMO Scale for Clinical Actionability of Molecular Targets, version 2 (ESCAT v2): an evidence-based framework for ranking alterations as actionability and resistance biomarkers in precision oncology.","authors":"Aya El Helali, Claudia Cardone, Niamh Coleman, Juliana R Beal, Mel Valerie Cruz-Ordinario, Emre Kocakavuk, Matthew Kin-Liang Chiu, David Thomas, Clare Turnbull, Funda Meric-Bernstam, Maria Fernanda Mosele, Debyani Chakravarty, Rodrigo Dienstmann, David Tamborero, Hege E G Russnes, Maximilian Kordes, Herbert Ho Fung Loong, Albrecht Stenzinger, Jens Rueter, Diogo Martins-Branco, George Pentheroudakis, Joaquin Mateo, Christoph Benedikt Westphalen","doi":"10.1016/j.annonc.2026.09.008","DOIUrl":"https://doi.org/10.1016/j.annonc.2026.09.008","url":null,"abstract":"<p><strong>Background: </strong>Since the publication of the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT) in 2018, precision oncology has evolved substantially. Tumour-agnostic therapy approvals, expanding real-world evidence datasets, and the clinical recognition of genomic resistance biomarkers have created the need to revise the original framework.</p><p><strong>Methods: </strong>The ESMO Precision Oncology and Taxonomy Committee convened an international expert panel to revise the ESCAT classification. Through iterative review of the evolving evidence-base, structured feedback rounds, and consensus discussions, the panel developed an updated actionability scale and a novel resistance scale. The revision followed three principles: explicit grading of uncertainty within actionable tiers, formal inclusion of tumour-agnostic eligibility criteria, and systematic classification of resistance biomarkers to complement sensitivity designations.</p><p><strong>Results: </strong>ESCAT version 2 (ESCAT v2) introduces several substantive changes. Tier I is restructured into three categories, proven, inferred, and extrapolated, that carry the same clinical directive but differ in the level of certainty within the supporting evidence. The guideline introduces formal tumour-agnostic gating criteria, the ESMO Tumour-Agnostic Classifier and Screener (ETAC-S). Tier II is refined into three sub-tiers graded by prospective interventional evidence, high-quality real-world or non-prospective evidence, and replicated case-level evidence. Tier X is subdivided into alterations that are tested and found not to be predictive (X-A) and biomarker-therapy matches in which the therapy lacks meaningful activity in the biomarker-defined population (X-B). A parallel four-level resistance scale ranges from clinically validated resistance (contraindication) to preclinical or computational evidence (research use only).</p><p><strong>Conclusions: </strong>ESCAT v2 provides a comprehensive, evidence-graded framework for interpreting actionability and resistance biomarkers in cancer, enabling more nuanced communication among clinicians, patients, regulators, and researchers while preserving a clear directive to act when evidence supports patient benefit.</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":80.4,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149236752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书